Indivior Pharmaceuticals, Inc. has announced impressive financial results for the third quarter of 2026, showcasing a significant growth trajectory as it prepares to merge with Supernus Pharmaceuticals, Inc.

On October 29, 2026, Indivior reported total net revenue of $356 million for the quarter, marking a 13% increase compared to $314 million in the same period last year. The company highlighted record net revenue from its flagship product, SUBLOCADE, which generated $267 million, up 22% year-over-year.

This strong performance is attributed to the successful execution of the Indivior Action Agenda, which has driven growth in both revenue and net income. Indivior's net income for the quarter reached $137 million, while adjusted EBITDA soared to $211 million, reflecting a 76% year-over-year increase.

Background

Indivior Pharmaceuticals, Inc. operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is publicly traded on the Nasdaq under the ticker symbol INDV. Indivior, incorporated in Delaware, focuses on developing treatments for addiction and central nervous system disorders.

Recent filings show that Indivior has been active in the market, with multiple reports filed in October, including a merger agreement with Supernus Pharmaceuticals announced in August 2026. This merger is set to close on November 2, 2026, creating a larger, more diversified biopharmaceutical company.

What the Filing Says

According to the filing, "In the third quarter, we delivered record SUBLOCADE net revenue and record adjusted EBITDA, reflecting the strength of our business and the disciplined execution of the Indivior Action Agenda," stated Joe Ciaffoni, Chief Executive Officer of Indivior. The filing also noted that the company is on track to meet its previously communicated financial guidance for 2026.

Impact

The results and the impending merger with Supernus are expected to impact various stakeholders, including shareholders, employees, and patients relying on Indivior's products. The merger aims to create a leading CNS-focused biopharmaceutical company, potentially reshaping the competitive landscape in the pharmaceutical preparations sector.

What's Next

The merger with Supernus is anticipated to finalize on November 2, 2026. Following the merger, the combined company will operate as Supernus, Inc. and will begin trading under the ticker symbol SUPN on the Nasdaq Global Select Market starting November 3, 2026.